METTL3
METTL3 (methyltransferase 3, N6-adenosine-methyltransferase complex catalytic subunit, also known as MT-A70, Spo8 and M6A) is the catalytic core of the m6A methyltransferase complex. It methylates adenosine residues at the N(6) position of some RNAs, shaping mRNA stability, processing and translation. Browse Assay Genie's current range of METTL3 research reagents below, or read on for the biology behind the target.
METTL3 forms a heterodimer with METTL14, and within this N6-methyltransferase complex METTL3 constitutes the catalytic core. The complex places N6-methyladenosine (m6A) at 5'-[AG]GAC-3' consensus sites of some mRNAs. This mark influences mRNA stability, processing, translation efficiency and editing. Methylation is completed as mRNA is released into the nucleoplasm, and it generally promotes destabilisation and degradation of the transcript. METTL3 also acts as a positive regulator of translation independently of its methyltransferase activity, by interacting with the translation initiation machinery in the cytoplasm.
Through m6A, METTL3 regulates the circadian clock, hepatic lipid metabolism, differentiation of embryonic and haematopoietic stem cells, cortical neurogenesis, spermatogenesis and oogenesis. In embryonic stem cells, methylation of naive pluripotency transcripts destabilises them and promotes differentiation. In naive T-cells, methylation of SOCS1, SOCS3 and CISH transcripts promotes T-cell differentiation, and methylation of IFNB inhibits the type I interferon response. METTL3 also methylates primary miRNAs, marking them for recognition and processing by DGCR8, and methylates Xist RNA so that the reader YTHDC1 is targeted to it during random X inactivation. After ultraviolet irradiation it catalyses m6A formation at DNA damage sites, leading to POLK recruitment.
The METTL3 gene belongs to the MT-A70-like family, and the protein is found in the nucleus, nuclear speckles and cytoplasm. NCBI describes it as encoding the 70 kDa subunit of MT-A, hence the alias MT-A70. Its overexpression in a number of cancer cells suggests a role in proliferation through promotion of mRNA translation. During SARS-CoV-2 infection, METTL3 adds m6A to viral RNA, which decreases RIGI binding and dampens innate immune sensing.
METTL3 is the catalytic subunit that writes m6A on mRNA, making it central to studies of mRNA stability, processing and translation efficiency.
m6A deposition by METTL3 destabilises transcripts that govern pluripotency and cortical neurogenesis, promoting differentiation of embryonic stem cells and radial glial cells.
METTL3 controls T-cell differentiation through SOCS transcripts, limits type I interferon signalling via IFNB, and modifies SARS-CoV-2 RNA to dampen innate sensing.
METTL3 overexpression in cancer cells may promote proliferation via mRNA translation, and m6A is essential for spermatogenesis and oogenesis.
METTL3 is the catalytic core of the METTL3-METTL14 N6-methyltransferase complex, which methylates adenosine at the N(6) position of some RNAs to form m6A. This modification affects mRNA stability, processing, translation and editing. METTL3 can also promote translation independently of its methyltransferase activity.
METTL3 is also called MT-A70, Spo8 and M6A, and its previous name was methyltransferase like 3. The enzyme is classed as an N6-adenosine methyltransferase, EC 2.1.1.348. The MT-A70 name reflects the 70 kDa subunit of MT-A described in the NCBI Gene summary.
A mouse ortholog, Mettl3, exists. UniProt notes METTL3 overexpression in a number of cancer cells, suggesting a role in proliferation through mRNA translation. It also adds m6A to SARS-CoV-2 RNA, dampening innate immune sensing. Check the datasheet of any product for its validated reactivity.
Other METTL-family methyltransferases with research reagents at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt Q86U44; product specifications from Assay Genie datasheets.